Aims: To assess the relation of plasma viscosity to disease activity in patients with inflammatory bowel disease.
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Unit, The General Infirmary at Leeds, Leeds, LS1 3EX A J Lobo S C Jones L D Juby A T R Axon Correspondence to: Dr A J Lobo Accepted for publication 4 July 1991 Plasma viscosity can be used as a non-specific measure of the acute phase response" and may have several advantages over the more widely used erythrocyte sedimentation rate (ESR) . 24 The first clinical use of plasma viscosity measurement was described in 1942, when its use in pulmonary tuberculosis was described,5 and an association between red cell sedimentation velocity and plasma viscosity was noted. The widespread use of plasma viscosity measurement, however, was delayed until an automated system for its measurement became available. One such commercially available system has been shown to be reliable and precise3 and detailed guidelines for the assessment of the acute phase response, including the role of plasma viscosity, have been published. 2 The advantages of plasma viscosity are that, unlike the ESR, its value is independent of packed cell volume, sex, and for practical purposes, age.6 Viscosity is lower in neonates7 and rises slightly in the elderly due to changes in the plasma fibrinogen concentration. 8 The use of automated systems reduces the biohazard risks and produces reproducible, precise results and these can subjected to quality assurance. Plasma must be separated as soon as possible and never more than six hours after venesection, but once separated, its viscosity may remain stable for several days if kept at 15-200C.2
The initial capital cost of an automated viscometer is currently about £7500 with very low running costs. Measurement of ESR requires a very low initial outlay, but the subsequent running costs are higher. If the annual running costs are said to include laboratory disposables, appropriate venesection containers, a maintenance contract for the viscometer cost, interest repayments on the initial outlay for the viscometer and a sum to contribute to its eventual replacement, the approximate respective costs for performing 32 000 (the annual number performed at this institution in 1990) measurements of ESR and plasma viscosity would be £10 848 and £6464, respectively (P Day, personal communication). The initial capital outlay would therefore be recouped within two years and more rapidly if plasma viscosity was measured from the same blood container as the blood count.
There are few data on the use of plasma viscosity in clinical practice. In 1-92 (figure) ). There was a large overlap, however, between the two groups, and 10 of 21 (48%) patients with active disease had values within the reference range. In eight of these this normal plasma viscosity was associated with an increased CRP (median 77.5 mg/l; range 23-145), and in two the CRP was not increased.
Plasma viscosity was also higher in patients with active Crohn's disease compared with those with active ulcerative colitis (median 1 65 mPa.s; range 15-1-92). There was a trend towards increasing plasma viscosity with increasing disease severity in ulcerative colitis but this was not significant (r = 0-22; p = 0 07). Sensitivity and specificity ofplasma viscosity (PV) and ESR in distinguishing active from inactive Crohn's disease for different levels of both PV and ESR Sensitivity (00) Specificity This can also be expressed in terms of the sensitivity and specificity ofthe tests. These are, in turn, critically dependent on where the cutoff lines are drawn. The upper limit of the reference range in our laboratory is 1-72 mPa.s. This gives a specificity of 90% but a sensitivity of just 52%. In comparison, using an ESR of 20 as an upper limit, the sensitivity is much improved at 85%, but with a lower specificity of 71%. To obtain similar figures for the plasma viscosity would require the upper limit of the reference range to be dropped to 1 -65 mPa.s. At the levels currently used therefore, the ESR is more sensitive at detecting active Crohn's disease, but the plasma viscosity is more specific.
It has been pointed out that plasma viscosity may be less useful in conditions associated with anaemia and hypoalbuminaemia as both tend to increase the sedimentation rate.2 Crohn's disease is associated with both, although the hypoalbuminaemia may be partly due to the acute phase response. The anaemia of Crohn's disease may be multifactorial, but is partly related to disease activity, and the effect of an associated anaemia in increasing the sedimentation rate may make the ESR more sensitive. It is therefore of interest that in patients with Crohn's disease there was only a trend towards correlation between haemoglobin concentration and plasma viscosity. This presumably reflects a balance between the lack of effect of packed cell volume on viscosity and the common effect of disease activity by haemoglobin via the plasma protein concentration). The ESR has also been noted to 
